

Glycosylated Porphyrin Derivatives and Their Photodynamic Activity in Cancer Cells

Seenuvasan Vedachalam,^a Bo-Hwa Choi,^b Kalyan Kumar Pasunooti,^a Kun Mei Ching,^b Kijoon Lee,^c Ho Sup Yoon,^{*b} Xue-Wei Liu^{*a}

⁵ Received (in XXX, XXX) Xth XXXXXXXXX 200X, Accepted Xth XXXXXXXXX 200X

First published on the web Xth XXXXXXXXX 200X

DOI: 10.1039/b000000x

The present study reports the design and synthesis of nine C₂-symmetric 5,15-[bis(aryl)]-10 α ,20 β -[bis(1,2:3,4-di-O-isopropylidene- α -D-galactopyranose-6-yl)]porphyrins (**3-11**) bearing electron
10 donating or electron withdrawing substituents and a D₂-symmetric 5 α ,10 β ,15 α ,20 β -tetrakis(1,2:3,4-di-O-isopropylidene- α -D-galactopyranose-6-yl)porphyrin (**12**). In the system we design, the C₆ of pyranose sugar is elegantly fused into the porphyrin core as *meso* carbon, which renders a new type of photodynamic inducers. The biological effects of these derivatives were assessed in HeLa and HCT116 human cancer cells. In particular, the tetra-glycofused structure **12** exhibited the highest
15 cellular uptake and photocytotoxicity. Unlike the reported sugar-porphyrin conjugates, which normally localize in mitochondria or endoplasmic reticulum, the unique glycofused porphyrins in this study were dominantly localized in lysosomes. The measurement of the dual fluorescence of annexin V-FITC/PI by flow cytometry revealed that the cell death was caused by apoptosis. Further PARP cleavage study suggested that apoptosis induced by the treatment of compound **12** was *via*
20 caspase-dependent apoptotic pathway in cancer cells.

Introduction

Photodynamic therapy (PDT)¹ is a rapidly growing method used to treat various cancers including multidrug resistance² (MDR) phenotype tumor cells by using non-toxic photosensitizers (PSs)
25 and innocuous visible light in the presence of molecular oxygen. This technique is based on the generation of cytotoxic reactive oxygen species (ROS) by a PS under light irradiation.³ Currently, a few potent PSs such as porphyrins,⁴ phthalocyanines,⁵ perylene,⁶ cholin derivatives⁷ are commonly used in
30 photodynamic therapy. They are suitable PSs due to their light absorption in the visible range of spectrum, but early generation of these molecules has obvious drawbacks such as low tissue selectivity, low sensitizing efficiency, low solubility, high systemic toxicity, *etc.* Therefore, the development of new PS that
35 targets the abnormal cells selectively and generates cytotoxic ROS efficiently is one of the current strategies that are being explored.

Conjugation of porphyrin with cancer cell recognizing biomolecules is an active area receiving much attention,
40 especially the use of biological active sugar motifs as a conjugate.

^aDivision of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371. Fax: (65) 6791 1961; Tel: (65) 6316 8901; E-mail: xuewei@ntu.edu.sg

^bDivision of Structural and Computational Biology, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551. Tel: (65) 6316 8901; E-mail: hsyoon@ntu.edu.sg

^cDivision of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore 637457

† Electronic Supplementary Information (ESI) available: Experimental procedures and compound characterization data; experimental procedures, materials and methods for bioassay. See DOI: 10.1039/b000000x/

55 Previous studies described the roles of saccharides in cell recognition, with porphyrin-saccharide derivatives exhibiting much higher binding affinity to human cancer cell lines than their non-saccharide counterparts^{9,10}, with the sugar moieties enhancing uptake by cancer cells. Intelligibly, such
60 glycoconjugate porphyrin is thus a potential avenue for targeted photosensitizers towards tumor cells.⁹ In this work, we aim to develop a new series of sugar-porphyrin conjugates and investigate their potential phototoxicity, cellular localization studies, and *in vitro* apoptotic activities.

65 Results and Discussion

Rational Design of Glycofused Porphyrins as PSs.

Porphyrin derivatives are commonly used PSs due to their light absorption in the visible range of the spectrum and efficient phototoxicity towards cancer cells.¹¹ In the past decade, great
70 efforts have been made to search for more efficient photosensitizing molecules by modification of the porphyrin core and peripheral structure of phthalocyanines. Not surprisingly, tumor-recognizing elements, such as monoclonal antibodies have also been extensively explored to gain tissue selectivity and
75 reduce systemic toxicity. Synthesis of sugar-porphyrin conjugates were reported sporadically, but in most cases, the biologically active sugars were included into the peripheral structures with a linker between sugar moiety and the photosensitizing core structure (such as Fig. 1, structure A). Van Nostrum and
80 coworkers demonstrated the peripheral and axial substitution of phthalocyanines with solketal protected sugar groups (Fig. 1, structure B) facilitates an increased cellular uptake of cancer cells.¹² The solketal group was thought to act as a targeted

micelle, resulting in a higher intracellular concentration of the PS and a concomitant increase in photodynamic effect. This





Fig. 1. Rational design of new glycofused porphyrin photosensitizers. **A**, reported photosensitizing porphyrins, R = various groups including sugars; **B**, glycoconjugated phthalocyanines; **C**, tolyporphyrin A; **D**, glycofused porphyrins in this study.

biocompatible sugar unit is used to enhance the cellular uptake through over-expressed glucose transporters in cancer cells.¹³ The isopropylidene protecting group renders the compound metabolically stable and increase the cell availability of phthalocyanine conjugate that can be cleaved *in vivo* to form hydrophilic free hydroxyl units.¹⁴ The molecular design in this study was also inspired by a naturally occurring sugar-porphyrin conjugate, tolyporphyrin A¹⁵ (Fig. 1, structure C). It has a C₂ symmetric structural skeleton and the sugar moieties are directly linked to porphyrin. This structural skeleton has the ability to reverse the multidrug resistance (MDR) tumor cells.^{2,15} This suggests that conjugating pattern of sugar moieties with porphyrin core also plays an important role for their biological activity. Based on all above and our experience in carbohydrate chemistry and molecular design,¹⁶ we designed the glycofused porphyrins as shown in Fig. 1D. In structure D, two *para meso* positions of porphyrin structure were elegantly fused with the C₆ of isopropylidene protected galactose, and the other two *para meso* positions of the porphyrin structure were still decorated with aryl substitutions (**3-11**). The potential efficacy of our design is also strongly supported by Banfi and coworkers' work.⁴ They showed that diaryl porphyrin derivatives are more effective than corresponding tetraaryl porphyrin derivatives in inducing photodynamic cell elimination of human colon adenocarcinoma cells. In addition, two *para meso* positions of porphyrin structure were incorporated with similar sugar units, giving us tetrasugar porphyrin (**12**). We decided to choose galactose as a model sugar because Griegel and co-workers¹⁷ recognized that human retinoblastoma cells express sugar receptors that exhibits a preferential affinity for galactose residues and renders easy assimilation.

Synthesis of Glycofused Porphyrins.

Among the various resources from which a porphyrin ring can

be constructed, the acid-catalyzed condensation of dipyrromethane units with aryl aldehydes represents a widely used route, which we have exploited to obtain *meso* bis-glycosylated diarylporphyrins in this study. This approach takes advantage of the accessibility of homochiral dinuclear C-glycosyl dipyrromethane unit by a protocol involving the direct condensation of sugar aldehyde with pyrrole (Scheme 1). Thus, the condensation of 1,2:3,4-di-*O*-isopropylidene- α -D-galacto-hexadialdo-1,5-pyranose (**1**) with pyrrole (1:5 molar ratio) and 0.1 equiv of BF₃·Et₂O was effected in dichloromethane at room temperature. The reaction was completed within 1 h, after quenching with NaHCO₃(aq) and flash chromatography, the dipyrromethane sugar unit was obtained in 65% isolated yield. With significant quantity of dipyrromethane sugar in hand, we proceeded to construct the macrocycle. The condensation of the 1,2:3,4-di-*O*-isopropylidene-5,5-dipyrryl-6-deoxy- α -D-galactopyranose (**2**) with various aromatic aldehydes and sugar aldehyde (**1**) was performed according to the procedures developed by Casiraghi and coworkers.¹⁸ The porphyrin-ring construction was carried out by using various aldehydes with dipyrromethane (**2**) and BF₃·Et₂O in dry dichloromethane under argon atmosphere. The porphyrinogen intermediate was then oxidized by DDQ and further purification by flash chromatography yielded porphyrins **3-12** ranging from yields of 5% to 16% (Scheme 1). All the compounds are highly soluble in common organic solvents and deprotection of the isopropylidene group was not performed due to the instability of the compounds even under slightly acidic condition.



Scheme 1. Expedited synthesis of glycofused porphyrin conjugates.

Characterization and Spectral Properties.

The ¹H and ¹³C NMR spectra of 1,2:3,4-di-*O*-isopropylidene-5,5-dipyrryl-6-deoxy- α -D-galactopyranose (**2**) displayed distinct peaks for the pyrrole methyne proton and proton owing to the diastereotopicity of the two pyrrole units attached at the homochiral sugar fragment. The porphyrin conjugates **3-12** were subjected to various spectral analyses, including ¹H NMR, ¹³C NMR, mass spectrometry, UV-Vis, and IR spectroscopy. All the compounds are homogeneous and have reliable spectral values. From the ¹H NMR spectra of all the porphyrin compounds, it was observed that the ring system is highly conjugated and aromatic.

In general, the protons at the following positions are responsible for the signals in the indicated regions of the spectra (Fig. 1S): (a) pyrrole β , β' -protons (10.5 and 8.5 ppm), (b) *meso* phenyls and other aromatic protons (8.5 to 7.0 ppm), (c) sugar C-5' protons (7.7 to 6.8 ppm), (d) sugar C-1' anomeric proton (6.5 to 6 ppm), (e) other protons on the sugar legs (5.5 to 4.5 ppm), (e) four different methyl groups present in the isopropylidene groups (2.0 to 1.0 ppm), (f) characteristic NH proton (-2 to -3 ppm). The data suggest a minute chemical shift to the more deshielded region for the sugar methylenic proton as compared to the expected shift because it is directly linked with highly conjugated aromatic system. The diaryl sugar porphyrin (**3-11**) displayed two types of β , β' -pyrrole protons and five signals effect from sugar methylenic protons, thereby proving the presence of C_2 symmetry. Also, the integral value of the methylenic proton sugar unit illustrates a highly C_2 symmetric nature of the compounds. In contrast, compound **12** showed eight pyrrole β , β' -protons as a singlet and all the methylene protons of four sugars displayed only five signals which emphasizes the presence of D_2 symmetry. High resolution mass spectra (HRMS) gave molecular weights which are those expected for the corresponding $(M+H)^+$ formula and it is in good agreement (within 0.5 ppm) with the theoretical values (Table 1). In the UV-Vis spectra, the Soret bands at 403-419 nm and four Q bands at 500-620 nm showed the characteristic of a porphyrin ring (Table 1). For most of the electron donating substituents, the Soret bands were significantly red-shifted compared to the reference porphyrin compound **3**. In the Q-band region, similar spectral variation were obtained for all electron withdrawing substituents compared to the reference porphyrin compound **3**.

Table 1. UV & HRMS data of sugar-porphyrin conjugate.

Compd	UV-visible spectrum: λ_{max} nm (log ϵ)	HRMS (ESI): m/z $(M+H)^+$ (Calcd)
3	406 (4.478), 516 (4.136), 549 (3.749), 589 (3.672), 644 (3.549)	919.3948 (919.3918)
4	419 (4.506), 518 (3.577), 550 (3.103), 590 (3.106), 645 (2.811).	1009.3619 (1009.3620)
5	416 (4.480), 516 (3.453), 548 (3.051), 590 (2.979), 644 (2.723)	919.3138 (987.3139)
6	414 (4.540), 518 (4.282), 550 (3.817), 591(3.796), 640 (3.30)	1011.3665 (1011.3673)
7	414 (4.494), 518 (3.514), 550 (3.412), 590 (3.160), 646 (2.890)	979.4128 (979.4129)
8	412 (4.533), 516 (4.205), 546 (3.607) 590 (3.768), 644 (3.526)	1039.4347 (1039.4341)
9	403 (4.538), 516 (4.211), 550 (3.827), 591(3.757), 645 (3.487)	1087.3545 (1087.3564)
10	405 (4.521), 513 (4.163), 543 (3.422), 586 (3.701), 640 (3.163)	1099.2979 (1099.2976)
11	412 (4.501), 518 (3.767), 550 (3.480), 591 (3.329), 646 (3.089).	931.3044 (931.3047)
12	406 (4.519), 519 (4.017), 552 (3.381), 591(3.591), 646(3.437)	1223.5266 (1223.5288)

Cellular Phototoxicity.

The light dose-dependent phototoxicity of the photosensitizers was investigated in two different human cancer cell lines, HeLa and HCT116 by MTS assay at a concentration of 1 μ M. Among the ten compounds studied, four compounds (**5**, **6**, **11**, and **12**) have shown the phototoxic effects in both cancer cell lines (Fig.




Fig. 2. Dose-response curve obtained with compounds **5**, **6**, **11**, and **12** in HeLa (A) and HCT116 (B) cells. Cells were photosensitized with 1 μ M of each compound and the light dose was varied as indicated. Viability was assessed by MTS assay.




Fig. 3. Cellular uptake. HeLa cells were treated with 1 μ M of each compound for 24 h, rinsed, and fixed with 3.7% PFA. Fluorescence images were taken under identical conditions. Compound **12** is preferentially taken up by HeLa cells over compounds **5**, **6**, and **11**.

2. A and B) while the rest six compounds showed marginal phototoxicity (data not shown). In addition, those compounds exhibited a minor dark cytotoxicity in both cell lines, which maintained more than 90% of survival rate. On the other hand, the control cells irradiated in the absence of the photosensitizer were found to be negligible in cell death. These results suggest that the electron donating substituents present in the *para* position of the phenyl group, especially *p*-methoxy (**5**) and *p*-thiomethoxy

(6), enhance phototoxicity, compared with the electron withdrawing groups (pentafluoro, *p*-chloro and *p*-nitro, **8-10**) and simple phenyl substituent (**3**). Similarly, 3-thiophenyl group present in compound **11** showed good activity due to its electron donating nature. In contrast, the methoxy group present at *ortho* position of the phenyl ring of compound **4** and trifluoromethoxy at *para* position of the phenyl ring of compound **7** did not show any activity. However, phenyl group replaced by sugar unit called tetra-sugar porphyrin (**12**) conjugates exhibited quite reasonable phototoxicity. These results further supported that the cancer cells are sensitive to the photosensitizers. The amount of the photosensitizers taken up by the cells was determined by fluorescence microscopy after 24 h treatment. As shown in Fig. 3, compounds **5** and **6** were poorly internalized by HeLa cells compared with compounds **11** and **12**. Thus, the extent of uptake of the conjugates is dependent upon the nature of the sugar component and the electron donating nature of the substituent attached at *meso* position of the porphyrin ring. The cellular uptake of conjugates **12** was 3-8 times higher than that of porphyrin **5**, **6** & **11** at all time points studied under the same testing condition. It has been postulated that isopropylidene-protected sugar groups from the porphyrin residues play an important role in facilitating cellular uptake, probably through deprotection of soloketal group and may contribute to the formation of free hydroxyl group due to the acidic environment of cancer cells.¹⁹

Subcellular Localization.

The precise phototoxic effect of compound **12** was evaluated by examining its subcellular localization in HeLa cells. To this end, its fluorescence pattern was monitored with the organelle-specific fluorescent probes LysoTracker-Red and MitoTracker-Deep Red




Fig. 4. Intracellular localization of compounds. Subcellular localization of compound **12** determined by confocal laser scanning microscopy. HeLa cells treated with compound **12** were loaded with specific probes for lysosomes and mitochondria. Compound **12** (green) is shown in the left panels, LysoTracker or MitoTracker (Red) is shown in the middle panels, and an overlay of compound **12** with LysoTracker or MitoTracker (yellow) is shown in the right panels

by fluorescence microscopy, which target lysosomes and mitochondria, respectively. As shown in Fig. 4, compound **12** is primarily localized in lysosomes. In addition, the subcellular localization was also examined in HCT116 cells, showing the similar pattern as seen in HeLa cells (data not shown). Turk and

coworkers reported that apoptosis can be induced by selectively disrupting lysosome, through the cleavage by papain-like cathepsins independent of caspase activation.²⁰ Several cathepsins were shown to cleave Bid and assist cytochrome *c* release from mitochondria in the presence of Bid *in vitro*, indicating their redundant roles. However, we cannot exclude the possibility that lysosomal proteases can also activate apoptosis other than Bid-mediated apoptotic pathways, prompting us to check the underlying molecular mechanism of the novel PDT compound.

Studies on PDT Induced Apoptotic Cell Death.

In order to delineate cell death mechanism²¹ in response to the treatment of compound **12**, standard apoptotic assays were performed. As shown in Fig. 5, a majority of the non-illuminated cells appeared annexin V-negative section, whereas 80% of the illuminated HeLa cell population was annexin V-positive.




Fig. 5. Compound **12** with PDT induces apoptotic cell death in HeLa cells. HeLa cells were treated with or without 1 μ M compound **12** for 24 h and were illuminated with 50 W halogen lamp (0.2 kJ/cm²). After 24 h, cells were co-stained with fluorescent annexin V and propidium iodide and then examined for apoptosis by flow cytometry.

Studies about Nuclear Condensation and Fragmentation.

Similar results were obtained from the nuclear condensation and fragmentation analysis. The significant nuclear fragmentation occurred 24 h after light exposure with compound **12** in HeLa cells (Fig. 6). In contrast, cells treated with compound **12** without illumination did not exhibit significant changes in nuclear fragmentation analyses (Fig. 6).




Fig. 6. Compound **12** with PDT induces apoptotic cell death in HeLa cells. Nuclear condensation or fragmentation, one of typical apoptotic features, was assessed by nuclei staining with DAPI after cells were treated with or without 1 μ M compound **12** with PDT. Images were visualized using a fluorescent microscope and captured with a CCD camera. Arrow indicates normal nuclei.

Studies on PARP Cleavage.

Based on our experience,²² next, we also checked poly (ADP-ribose) polymerase (PARP) cleavage after compound treatment. PARP is a DNA repair enzyme whose expression is triggered by DNA strand breaks, and one of caspase-3 targets. If cells undergo apoptosis, PARP with 113 kD peptide is cleaved into 24 and 89 kD polypeptides by active caspase-3. We found that the treatment with compound **12** resulted in a cleavage of 113 kD PARP to 85 kD in HeLa cells, which was most dramatic in cells at 24 h after treatment with PDT (Fig. 7). The results were consistent with the phototoxicity effect of compound **12**. Taken together, our data suggest that apoptosis induced by the treatment of compound **12** was *via* caspase-dependent apoptotic pathway in cancer cells.




Fig. 7. Compound **12** with PDT induces apoptotic cell death in HeLa cells. Cells were treated with or without 1 μ M compound **12** for 24 h and irradiated, and 24 h after irradiation, cells were collected and lysed. The supernatant of the lysate was applied to immunoblotting to detect PARP cleavage. C, untreated cells; D, cells incubated with compound **12** without irradiation; 0 and 24, designate time points of cell harvest after irradiation (0.2 kJ/cm²).

Conclusions

A series of glycofused porphyrin derivatives with C₂ and D₂ symmetry, **3-12** have been designed and efficiently prepared. Their structures were fully confirmed by spectroscopic techniques, and their spectral properties were well characterized. The derivatives **5**, **6**, **11**, and **12** showed significant cellular uptake and photocytotoxicity in HeLa cells and HCT116 cells, respectively at a concentration of 1 μ M. In particular, the tetra-glycofused structure **12** exhibited the highest cellular uptake and photocytotoxicity. Unlike the reported sugar-porphyrin conjugates, which normally localize in mitochondria or endoplasmic reticulum, the unique glycofused porphyrins we designed in this study were dominantly localized in lysosomes. Sugar moieties in our molecules should take credit for the enhanced cellular uptake and also for the lysosome localization. The measurement of the dual fluorescence of annexin V-FITC/PI by flow cytometry revealed that the cell death was caused by apoptosis. Further PARP cleavage study suggested that apoptosis induced by the treatment of compound **12** was *via* caspase-dependent apoptotic pathway in cancer cells. The *in vivo* PDT efficacy of compound **12** is under investigation in our laboratory.

Acknowledgement

We thank Drs Malini Carolene Olivo and Patricia Thong for their kind advice for the experiments. Financial supports from Nanyang Technological University (RG50/08) and the Ministry of Health, Singapore (NMRC/H1N1R/001/2009 and NMRC/1177/2008) are gratefully acknowledged.

Notes and references

- a) J. F. Lovell, T. W. B. Liu, J. Chen and G. Zheng, *Chem. Rev.*, 2010, **110**, 2839; b) J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue and T. Hasan, *Chem. Rev.*, 2010, **110**, 2795; c) M. Ethirajan, Y. Chen, P. Joshi and R. K. Pandey, *Chem. Soc. Rev.*, 2010, DOI: 10.1039/B915149B; d) A. E. O'Connor, W. M. Gallagher and A. T. Byrne, *Photochem. Photobiol.*, 2009, **85**, 1053; e) A. P. Castano, P. Mroz and M. R. Hamblin, *Nat. Rev. Cancer*, 2006, **6**, 535; f) M. R. Detty, S. L. Gibson and S. J. Wagner, *J. Med. Chem.*, 2004, **47**, 3897; g) W. M. Sharman, J. E. van Lier and C. M. Allen, *Adv. Drug Delivery Rev.*, 2004, **56**, 53; h) D. E. J. G. J. Dolmans, D. Fukumura and R. K. Jain, *Nat. Rev. Cancer*, 2003, **3**, 380; i) M. A. Pathak and T. B. Fitzpatrick, *J. Photochem. Photobiol. B*, 1992, **14**, 3.
- P. Morlière, J.-C. Mazière, R. Santus, C. D. Smith, M. R. Prinsep, C. C. Stobbe, M. C. Fenning, J. L. Golberg and J. D. Chapman, *Cancer Res.*, 1998, **58**, 3571.
- a) L. V. Chekulayeva, V. A. Chekulayev and I. N. Shevchuk, *J. Photochem. Photobiol. B*, 2008, **93**, 94; b) D. A. Musser and A. R. Oseroff, *Photochem. Photobiol.*, 2001, **73**, 518.
- a) S. Banfi, E. Caruso, L. Buccafurni, R. Murano, E. Monti, M. Gariboldi, E. Papa and P. Gramatica, *J. Med. Chem.*, 2006, **49**, 3293; b) J. E. van Lier, H. Tian, H. Ali, N. Cauchon and H. M. Hasséian, *J. Med. Chem.*, 2009, **52**, 4107.
- F. Yukruk, A. L. Dogan, H. Canpinar, D. Guc and E. U. Akkaya, *Org. Lett.*, 2005, **7**, 2885.
- Y. Chen, W. R. Potter, J. R. Missert, J. Morgan and R. K. Pandey, *Bioconjugate Chem.*, 2007, **18**, 1460.
- a) M. Sibrian-Vazquez, T. J. Jensen, R. P. Hammer and M. G. H. Vicente, *J. Med. Chem.*, 2006, **49**, 1364; b) M. Obata, S. Hirohara, K. Sharyo, H. Alitomo, K. Kajiwara, S.-i. Ogata, M. Tanihara, C. Ohtsuki and S. Yano, *Biochim. Biophys. Acta.*, 2007, **1770**, 1204; c) A. A. Rosenkranz, D. A. Jans and A. S. Sobolev, *Immunol. Cell Biol.*, 2000, **78**, 452.
- a) S. Hirohara, M. Obata, H. Alitomo, K. Sharyo, T. Ando, S. Yano and M. Tanihara, *Bioconjugate Chem.*, 2009, **20**, 944; b) X. Zheng and R. K. Pandey, *Anticancer Agents Med. Chem.*, 2008, **8**, 241; c) M. Amessou, D. I. Carrez, D. Patin, M. Sarr, D. S. Grierson, A. Croisy, A. C. Tedesco, P. Maillard and L. Johannes, *Bioconjugate Chem.*, 2008, **19**, 532; d) D. Samaroo, M. Vinodu, X. Chen and C. M. Drain, *J. Comb. Chem.*, 2007, **9**, 998; e) J. P. C. Tomé, E. M. P. Silva, A. M. V. M. Pereira, C. M. A. Alonso, M. A. F. Faustino, M. G. P. M. S. Neves, A. C. Tomé, J. A. S. Cavaleiro, S. A. P. Tavares, R. R. Duarte, M. F. Caeiro and M. L. Valdeira, *Bioorg. Med. Chem.*, 2007, **15**, 4705; f) I. Laville, S. Pigaglio, J.-C. Blais, F. Doz, B. Loock, P. Maillard, D. S. Grierson and J. Blais, *J. Med. Chem.*, 2006, **49**, 2558; g) S. Hirohara, M. Obata, S.-I. Ogata, C. Ohtsuki, S. Higashida, S.-I. Ogura, I. Okura, M. Takenaka, H. Ono, Y. Sugai, Y. Mikata, M. Tanihara and S. Yano, *J. Photochem. Photobiol. B*, 2005, **78**, 7; h) X. Chen and C. M. Drain, *Drug Design Reviews-online*, 2004, **1**, 215; i) K. Fujimoto, T. Miyata and Y. Aoyama, *J. Am. Chem. Soc.*, 2000, **122**, 3558; j) C. Schell and H. K. Hombrecher, *Bioorg. Med. Chem.*, 1999, **7**, 1857; k) M. Mumentreau, P. Maillard, M. A. De Bélinary, D. Carrez and A. Croisy, *J. Biomed. Opt.*, 1999, **4**, 298.
- X. Chen, L. Hui, D. A. Foster and C. M. Drain, *Biochemistry*, 2004, **43**, 10918.
- E. D. Sternberg and D. Dolphin, *Tetrahedron*, 1998, **54**, 4151.
- J.-W. Hofman, F. van Zeeland, S. Turker, H. Talsma, S. A. G. Lambrechts, D. V. Sakharov, W. E. Hennink and C. F. van Nostrum, *J. Med. Chem.*, 2007, **50**, 1485.
- S. P. Zamora-León, D. W. Golde, I. I. Concha, C. I. Rivas, F. Delgado-López, J. Baselga, F. Nualart and J. C. Vera, *Proc. Natl. Acad. Sci. USA.*, 1996, **93**, 1847.
- a) C.-F. Choi, J.-D. Huang, P.-C. Lo, W.-P. Fong and D. K. P. Ng, *Org. Biomol. Chem.*, 2008, **6**, 2173; b) P.-C. Lo, C. M. H. Chan, J.-Y. Liu, W.-P. Fong and D. K. P. Ng, *J. Med. Chem.*, 2007, **50**, 2100; c) P. P. S. Lee, P.-C. Lo, E. Y. M. Chan, W.-P. Fong, W.-H. Ko and D. K. P. Ng, *Tetrahedron Lett.*, 2005, **46**, 1551.

15. M. R. Prinsep, G. M. L. Patterson, L. K. Larsen and C. D. Smith, *Tetrahedron*, 1995, **51**, 10523.
16. a) R. Lorpitthaya, Z. H. Xie, K. B. Sophy, J. L. Kuo, X.-W. Liu, *Chem. Eur. J.*, 2010, **16**, 588; b) R. Y. Yang, K. K. Pasunooti, F. Li, X.-W. Liu, and C.-F. Liu, *J. Am. Chem. Soc.*, 2009, **131**, 13592; c) H. G. Sudibya, J. Ma, X. Dong, S. Ng, L.-J. Li, X.-W. Liu and P. Chen, *Angew. Chem. Int. Ed.*, 2009, **48**, 2723; (d) B. K. Gorityala, R. Lorpitthaya, Y. Bai, X.-W. Liu, *Tetrahedron*, 2009, **65**, 5844; (e) R. Lorpitthaya, K. B. Sophy, J. L. Kuo and X.-W. Liu, *Org. Biomol. Chem.*, 2009, **7**, 1284; (f) B. K. Gorityala, S. Cai, R. Lorpitthaya, J. Ma, K. K. Pasunooti, X.-W. Liu, *Tetrahedron Lett.*, 2009, **50**, 676; (g) X.-W. Liu, T. N. Le, Y. P. Lu, Y. J. Xiao, J. M. Ma, X. Li, *Org. Biomol. Chem.*, 2008, **6**, 3997; (h) R. Lorpitthaya, Z.-Z. Xie, J.-L. Kuo, X.-W. Liu, *Chem. Eur. J.*, 2008, **14**, 1561; (i) X.-M. Cheng, X.-W. Liu, *J. Comb. Chem.*, 2007, **9**, 906-908.
17. S. R. Griegel, T. Ciesiolka and H. J. Gabius, *Anticancer Res.*, 1989, **9**, 723.
18. a) G. Casiraghi, M. Cornia, F. Zanardi, G. Rassa, E. Ragg and R. Bortolini, *J. Org. Chem.*, 1994, **59**, 1801. b) M. Cornia, G. Casiraghi, S. Binacchi, F. Zanardi and G. Rassa, *J. Org. Chem.*, 1994, **59**, 1226.
19. c) Y. Urano, D. Asanuma, Y. Hama, Y. Koyama, T. Barrett, M. Kamiya, T. Nagano, T. Watanabe, A. Hasegawa, P. L. Choyke and H. Kobayashi, *Nat. Med.*, 2009, **15**, 104.
20. T. Cirman, K. Orešić, G. D. Mazovec, V. Turk, J. C. Reed, R. M. Myers, G. S. Salvesen and B. Turk, *J. Biol. Chem.*, 2004, **279**, 3578.
21. a) Klara Stefflova, Juan Chen, Diane Marotta, Hui Li, and Gang Zheng, *J. Med. Chem.*, 2006, **49**, 3850; b) M. Lam, N. L. Oleinick and A.-L. Nieminen, *J. Biol. Chem.*, 2001, **276**, 47379.
22. a) B.-H. Choi, L. Feng and H. S. Yoon, *J. Biol. Chem.*, 2010, **285**, 9770; b) B.-H. Choi, W. Kim, Q. C. Wang, D.-C. Kim, S. N. Tan, J. W. H. Yong, K.-T. Kim and Yoon, H. S. *Cancer Lett.* 2008, **261**, 37.

20

25

30

35

40

45

50

55

60

65